LABELS · 721dbcb3-df3b-428c-a5e6-1c807025a14a

KENALOG-40

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-08-20
Captured: 2026-09-09T23:37:51.659493+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

Full extracted label fields

application numbers

NDA014901

boxed warning exact

brand names

KENALOG-40
KENALOG-80

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf970688-cd77-b95c-4bd9-c541590e9722

generic names

TRIAMCINOLONE ACETONIDE

721dbcb3-df3b-428c-a5e6-1c807025a14a

indications and usage exact

INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

indications and usage tables exact

is original packager

true

manufacturer names

E.R. Squibb & Sons, L.L.C.

matched search terms

cancer
lymphomas
tumor

package ndcs

0003-0293-05
0003-0293-20
0003-0293-28
0003-0315-05
0003-0315-20

product ndcs

0003-0293
0003-0315

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRA-ARTICULAR
INTRAMUSCULAR

rxcuis

1085754
1085756
1792144
2168081
2168083
2168095
2168097
2480108

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00400.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 755
end exclusive: true
exact text: INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 0

current approval status

not_reconciled

duplicate text group

dup-394c17a60537ddca2e26

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-7f8672ce857a36fdc16b

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

end: 228
end exclusive: true
exact text: is indicated
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 216

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 555
end exclusive: true
exact text: INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 923
end exclusive: true
exact text: ate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where a
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 356

current approval status

not_reconciled

duplicate text group

dup-17e977c2de6399e6ac57

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-f5fb2121d98de3c703e2

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 723
end exclusive: true
exact text: Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 556

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1307
end exclusive: true
exact text: ickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamo
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 524

current approval status

not_reconciled

duplicate text group

dup-139f41de5b007c1bfbf7

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-abded05e5c7cc3b17a96

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1107
end exclusive: true
exact text: Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 724

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1438
end exclusive: true
exact text: ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 908

current approval status

not_reconciled

duplicate text group

dup-8c7c9a39995993c71ced

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-5244d4732fb67852cf43

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1238
end exclusive: true
exact text: Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1108

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1595
end exclusive: true
exact text: a, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neopla
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1039

current approval status

not_reconciled

duplicate text group

dup-f4ab0227b4b604f60cbd

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-aa31ab63977d480ca715

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1395
end exclusive: true
exact text: Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1239

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1788
end exclusive: true
exact text: regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tu
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1196

current approval status

not_reconciled

duplicate text group

dup-fb4a30881ab40edaa85b

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-bd5c2c0415f6176d9510

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1588
end exclusive: true
exact text: Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1396

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1867
end exclusive: true
exact text: penia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteri
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1389

current approval status

not_reconciled

duplicate text group

dup-ff1ffd2def3cf5a257e3

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-d65f46a853f1a8c0fc49

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1667
end exclusive: true
exact text: Neoplastic diseases: For the palliative management of leukemias and lymphomas.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1589

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2006
end exclusive: true
exact text: berculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission o
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1468

current approval status

not_reconciled

duplicate text group

dup-fa3f07341defc7371018

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-ae092dc5ecc474ca75ee

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
kind
biomarker
polarity
not_inferred
span
end
1805
end exclusive
true
exact text
metastatic brain tumor or craniotomy
label id
721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start
1769
context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
kind
stage_or_setting
polarity
not_inferred
span
end
1805
end exclusive
true
exact text
metastatic brain tumor or craniotomy
label id
721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start
1769

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1806
end exclusive: true
exact text: Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1668

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2156
end exclusive: true
exact text: s: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulm
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1607

current approval status

not_reconciled

duplicate text group

dup-115856e0bc2ee2689a3e

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-5a6a48decd38d918e7d3

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1956
end exclusive: true
exact text: Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1807

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2288
end exclusive: true
exact text: primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptom
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1757

current approval status

not_reconciled

duplicate text group

dup-06ac76746ed7bea3bfee

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-dbd74c1c31a30e3988d8

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2088
end exclusive: true
exact text: Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1957

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2505
end exclusive: true
exact text: ar inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spo
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 1889

current approval status

not_reconciled

duplicate text group

dup-481a412930ece3312ae7

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-4c3f81405b13ad7703ac

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2305
end exclusive: true
exact text: Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 2089

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2856
end exclusive: true
exact text: ses: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injectio
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 2106

current approval status

not_reconciled

duplicate text group

dup-2d2835c74d8acbbdc153

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-a30dbcc824751a0d251e

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2656
end exclusive: true
exact text: Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 2306

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2942
end exclusive: true
exact text: hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patie
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 2457

current approval status

not_reconciled

duplicate text group

dup-7ea76e2eb0fee48f484d

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-74f490f4e699c3383e95

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2742
end exclusive: true
exact text: For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 2657

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · positive indication candidate

application numbers

NDA014901

brand names

KENALOG-40
KENALOG-80

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3137
end exclusive: true
exact text: oid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 2543

current approval status

not_reconciled

duplicate text group

dup-88b7a6741adefabdf952

extraction review status

automated_candidate_pending_source_review

generic names

TRIAMCINOLONE ACETONIDE

ind-span-c738852549beb8ef67d5

label id

721dbcb3-df3b-428c-a5e6-1c807025a14a

positive predicate support span

end: 2871
end exclusive: true
exact text: are indicated
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 2858

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 3137
end exclusive: true
exact text: Intra-Articular The intra-articular or soft tissue administration of KENALOG-40 Injection and KENALOG-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
label id: 721dbcb3-df3b-428c-a5e6-1c807025a14a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0b82fde64dff5fa442e5d224bfc94fa7e5771e27d48454a69ba0e60a6e7d868f
start: 2743

source url

https://api.fda.gov/drug/label.json?search=id%3A%22721dbcb3-df3b-428c-a5e6-1c807025a14a%22

spl effective date

2024-08-20

spl set id

cf970688-cd77-b95c-4bd9-c541590e9722

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice